Όλο το DSpace

Πλοήγηση ανά Θέμα "androgen deprivation therapy"

Αποτελέσματα 1-8 από 8

    • Adverse effects of androgen deprivation therapy in patients with prostate cancer: Focus on metabolic complications 

      Tzortzis V., Samarinas M., Zachos I., Oeconomou A., Pisters L.L., Bargiota A. (2017)
      Prostate cancer is the most common cancer among men and androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of the treatment of prostate cancer is inhibition of testosterone ...

    • Adverse effects of androgen deprivation therapy in patients with prostate cancer: Focus on muscle and bone health 

      Bargiota A., Oeconomou A., Zachos I., Samarinas M., Pisters L.L., Tzortzis V. (2020)
      Androgen deprivation therapy (ADT) is the most effective systemic treatment for prostate cancer and can be succeeded either surgically or pharmaceutically. Both approaches lead to hypogonadism with a large variety of adverse ...

    • Cancer-associated stroke: Pathophysiology, detection and management (Review) 

      Dardiotis E., Aloizou A.-M., Markoula S., Siokas V., Tsarouhas K., Tzanakakis G., Libra M., Kyritsis A.P., Brotis A.G., Aschner M., Gozes I., Bogdanos D.P., Spandidos D.A., Mitsias P.D., Tsatsakis A. (2019)
      Numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in cancer patients is discussed, while providing vital ...

    • Drug-induced endocrinopathies and diabetes: A combo-endocrinology overview 

      Diamanti-Kandarakis E., Duntas L., Kanakis G.A., Kandaraki E., Karavitaki N., Kassi E., Livadas S., Mastorakos G., Migdalis I., Miras A.D., Nader S., Papalou O., Poladian R., Popovic V., Rachoń D., Tigas S., Tsigos C., Tsilchorozidou T., Tzotzas T., Bargiota A., Pfeifer M., on behalf of COMBO ENDO TEAM: 2018 (2019)
      In the currently overwhelming era of polypharmacy, the balance of the dynamic and delicate endocrine system can easily be disturbed by interfering pharmaceutical agents like medications. Drugs can cause endocrine abnormalities ...

    • Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer 

      Alexidis P., Karatzoglou S., Dragoumis D., Drevelegas K., Tzitzikas I., Hatzimouratidis K., Chrisogonidis I., Ioannidis A., Katsios I.N., Zarogoulidis P., Sapalidis K., Koulouris C., Michalopoulos N., Giannakidis D., Aidoni Z., Fyntanidou V., Amaniti A., Boniou K., Kesisoglou I., Vagionas A., Romanidis K., Oikonomou P., Goganau A.M., Petanidis S., Maragouli E., Kosmidis C. (2020)
      Background: Prostate cancer is considered to be highly sensitive to changes in radiation therapy dose per fraction, specifically to hypofractionation. An increase in the fractionation dose could cause a higher increase to ...

    • Prostate cancer: ESMO consensus conference guidelines 2012 

      Horwich, A.; Hugosson, J.; de reijke, T.; Wiegel, T.; Fizazi, K.; Kataja, V.; Parker, C.; Bellmunt, J.; Berthold, D.; Bill-axelson, A.; Carlsson, S.; Daugaard, G.; De meerleer, G.; De reijke, T.; Dearnaley, D.; Fonteyne, V.; Gillessen, S.; Heinrich, D.; Kwiatkowski, M.; Nilsson, S.; Padhani, A.; Papandreou, C.; Roobol, M.; Sella, A.; Valdagni, R.; Van der kwast, T.; Verhagen, P. (2013)
      The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological ...

    • The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: Early results of a randomized trial 

      Alexidis P., Dragoumis D., Karatzoglou S., Drevelegas K., Tzitzikas I., Hatzimouratidis K., Chrisogonidis I., Giannakidis D., Koulouris C., Katsaounis A., Michalopoulos N., Huang H., Li Q., Aidoini Z., Fyntanidou V., Amaniti A., Hohenforst-Schmidt W., Maragouli E., Petanidis S., Zarogoulidis P., Sapalidis K., Kosmidis C., Romanidis K., Oinkonomou P., Vagionas A., Nikolaos-Katsios I., Ioannidis A., Boniou K., Kesisoglou I. (2019)
      Background: Prostate cancer is considered to have a special biology which could affect the radiation therapy result based on the selected fractionation scheme. We present the preliminary results of a randomized trial ...

    • Targeting neuroendocrine prostate cancer: Molecular and clinical perspectives 

      Vlachostergios, P. J.; Papandreou, C. N. (2015)
      Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation ...